CTT Pharmaceutical Holdings, Inc. filed a Form 10-Q with the SEC on November 18, 2026, reporting unaudited financial results for the quarterly period ended September 30, 2026.

Key Highlights

  • Net loss of $127,064 for the three months ended September 30, 2026, compared to a net loss of $15,379 for the same period in 2025, according to the filing.
  • Total assets of $78,326 as of September 30, 2026, down from $86,168 as of December 31, 2025, the filing disclosed.
  • Accumulated deficit of $7,778,435 as of September 30, 2026, per the balance sheet.
  • 1,150,000 common shares issued for services during the three months ended September 30, 2026, valued at $112,000, the filing stated.
  • 61,516,676 shares outstanding as of September 30, 2026, up from 58,837,232 at December 31, 2025, according to the filing.
  • No revenue was reported for the periods covered, as the company disclosed it "had no revenue-producing activities" as of September 30, 2026.
  • Cash of $12,625 at the end of the quarter, down from $15,359 at December 31, 2025, per the balance sheet.

CTT Pharmaceutical Q3 2026 Financials: Losses Widen, Shares Issued for Services

CTT Pharmaceutical Holdings, Inc., a Florida-incorporated company focused on fast-dissolving drug delivery systems, reported a net loss of $127,064 for the three months ended September 30, 2026, according to its quarterly filing. This compares to a net loss of $15,379 for the three months ended September 30, 2025. The primary driver of the increased loss was consulting fees of $112,000 in the current quarter, versus $5,000 in the prior-year quarter, the filing disclosed.

The company's balance sheet as of September 30, 2026 showed total assets of $78,326, consisting of $12,625 in cash and $65,701 in intangible assets, net. Total current liabilities stood at $37,347, including related-party payables of $17,905 and a related-party note payable of $19,442. Total stockholders' equity was reported at $40,979, down from $55,150 at December 31, 2025, per the filing.

For the nine months ended September 30, 2026, the company reported a net loss of $226,972 and net cash used in operating activities of $43,534, according to the cash flow statement. Financing activities provided $40,800 from the sale of common shares during the nine-month period. The company issued 1,150,000 shares for services valued at $112,000 and 644,444 shares for cash proceeds of $30,000 during the three months ended September 30, 2026, the filing stated. Management evaluated subsequent events through the financial statement issuance date and noted, according to the filing, "no material events requiring disclosure."

What Was Disclosed

CTT Pharmaceutical Holdings filed its unaudited quarterly report covering the period ended September 30, 2026, disclosing a net loss of $127,064, total assets of $78,326, an accumulated deficit of $7,778,435, and no revenue-producing activities for the period.